Nektar Therapeutics
Nektar Therapeutics (Nasdaq: NKTR) is a clinical-stage, research-based biopharmaceutical company focused on discovering and developing immunotherapy medicines. Its pipeline targets autoimmune and inflammatory diseases, including rezpegaldesleukin and the preclinical candidates NKTR-0165 and NKTR-0166, as well as… From the company’s description.
Over the twelve months to Jun 30, 2026, Nektar Therapeutics reported revenue of $54.59M, down 27.2% from a year earlier, and a net loss of $157.13M. Its operating margin was −257.8%, and operations used $233.79M in cash. In fiscal 2025, it reported revenue of $55.23M, down 43.9% from fiscal 2024, and a net loss of $164.08M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Nektar Therapeutics does
In the company’s own words
Nektar Therapeutics (Nasdaq: NKTR) is a clinical-stage, research-based biopharmaceutical company focused on discovering and developing immunotherapy medicines. Its pipeline targets autoimmune and inflammatory diseases, including rezpegaldesleukin and the preclinical candidates NKTR-0165 and NKTR-0166, as well as cancer, including NKTR-255. Rezpegaldesleukin is being studied for atopic dermatitis and alopecia areata, while NKTR-255 is evaluated in combination with cell therapies and checkpoint inhibitors. Nektar also conducts discovery research across proteins, peptides and antibodies and develops candidates using polymer-conjugate technology, including PEGylation. The company has a single focus on research and development rather than reportable operating segments. It selectively collaborates with pharmaceutical and biotechnology partners on development, licensing, manufacturing and commercialization; its technology has been used in more than ten products approved in the United States or Europe, including ADYNOVATE, MOVANTIK, CIMZIA and MIRCERA. Nektar regained full rights to rezpegaldesleukin after Lilly terminated its license agreement in 2023. Its website is www.nektar.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 906709
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Nektar Therapeutics — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Nektar Therapeutics’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Nektar Therapeutics and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Nektar Therapeutics's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Nektar Therapeutics's last four quarterly filings that the numbers alone won't show?”